Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ReNeuron's Cell Therapy Garners Excitement In RP-Related Vision Loss

Executive Summary

A surprisingly strong improvement in vision has accompanied the use of proprietary stem cells in the first three retinitis pigmentosa patients in a US Phase II study, intriguing the UK biotech, ReNeuron, and maybe attracting development partners too.

You may also be interested in...



MeiraGTx Signs J&J To Develop Gene Therapies For Rare Retinal Diseases

While it wants to keep other programs for diseases with larger patient populations in house, MeiraGTx believes J&J offers the global reach to expedite its program in inherited retinal diseases, including three clinical candidates.

Luxturna Approved In EU: Novartis Outlines Lessons For Gene Therapy Strategies

The European Commission has officially approved Luxturna, Novartis/Spark Therapeutics’ transformative gene therapy. The Swiss firm tells Scrip how the lessons it expects to learn from launching its first gene therapy will inform its future strategy in this new field.

Merck's Keytruda Stakes Its Claim To First-Line Use In Advanced Cervical Cancer

Combining Merck & Co’s pembrolizumab with chemotherapy first-line improves survival and PFS in metastatic cervical cancer, reinforcing its position in a condition in the sights of a number of other companies, although usually in later lines of therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel